JAZZ
Price
$123.73
Change
-$0.52 (-0.42%)
Updated
Dec 24 closing price
69 days until earnings call
REGN
Price
$714.47
Change
-$0.66 (-0.09%)
Updated
Dec 24 closing price
37 days until earnings call
Ad is loading...

JAZZ vs REGN

Header iconJAZZ vs REGN Comparison
Open Charts JAZZ vs REGNBanner chart's image
Jazz Pharmaceuticals
Price$123.73
Change-$0.52 (-0.42%)
Volume$187.95K
CapitalizationN/A
Regeneron Pharmaceuticals
Price$714.47
Change-$0.66 (-0.09%)
Volume$382.15K
CapitalizationN/A
JAZZ vs REGN Comparison Chart
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. REGN commentary
Dec 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a StrongBuy and REGN is a Hold.

COMPARISON
Comparison
Dec 26, 2024
Stock price -- (JAZZ: $123.73 vs. REGN: $714.47)
Brand notoriety: JAZZ: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 30% vs. REGN: 43%
Market capitalization -- JAZZ: $7.48B vs. REGN: $78.51B
JAZZ [@Biotechnology] is valued at $7.48B. REGN’s [@Biotechnology] market capitalization is $78.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 0 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • JAZZ’s TA Score: 4 bullish, 3 bearish.
  • REGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both JAZZ and REGN are a good buy in the short-term.

Price Growth

JAZZ (@Biotechnology) experienced а +1.01% price change this week, while REGN (@Biotechnology) price change was -3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.88%. For the same industry, the average monthly price growth was -1.84%, and the average quarterly price growth was +2.99%.

Reported Earning Dates

JAZZ is expected to report earnings on Mar 04, 2025.

REGN is expected to report earnings on Jan 31, 2025.

Industries' Descriptions

@Biotechnology (-0.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($78.5B) has a higher market cap than JAZZ($7.48B). REGN (17.67) and JAZZ (17.53) have similar P/E ratio . JAZZ YTD gains are higher at: 0.593 vs. REGN (-18.652). REGN has higher annual earnings (EBITDA): 5.5B vs. JAZZ (1.31B). REGN has more cash in the bank: 9.8B vs. JAZZ (2.62B). REGN has less debt than JAZZ: REGN (2.7B) vs JAZZ (6.2B). REGN has higher revenues than JAZZ: REGN (13.8B) vs JAZZ (3.99B).
JAZZREGNJAZZ / REGN
Capitalization7.48B78.5B10%
EBITDA1.31B5.5B24%
Gain YTD0.593-18.652-3%
P/E Ratio17.5317.6799%
Revenue3.99B13.8B29%
Total Cash2.62B9.8B27%
Total Debt6.2B2.7B229%
FUNDAMENTALS RATINGS
JAZZ vs REGN: Fundamental Ratings
JAZZ
REGN
OUTLOOK RATING
1..100
7163
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
6351
PRICE GROWTH RATING
1..100
4764
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAZZ's Valuation (62) in the Pharmaceuticals Other industry is in the same range as REGN (65) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to REGN’s over the last 12 months.

REGN's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for JAZZ (100) in the Pharmaceuticals Other industry. This means that REGN’s stock grew somewhat faster than JAZZ’s over the last 12 months.

REGN's SMR Rating (51) in the Biotechnology industry is in the same range as JAZZ (63) in the Pharmaceuticals Other industry. This means that REGN’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as REGN (64) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (91) in the Biotechnology industry is in the same range as JAZZ (100) in the Pharmaceuticals Other industry. This means that REGN’s stock grew similarly to JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZREGN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
50%
MACD
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
60%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 17 days ago
63%
Declines
ODDS (%)
Bearish Trend 8 days ago
59%
Bearish Trend 6 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
44%
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
58%
View a ticker or compare two or three
Ad is loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA462.2831.68
+7.36%
Tesla
BTC.X98676.0900003989.851600
+4.21%
Bitcoin cryptocurrency
AAPL258.202.93
+1.15%
Apple
SPY601.306.61
+1.11%
SPDR® S&P 500® ETF Trust
GME31.140.24
+0.78%
GameStop Corp

JAZZ and

Correlation & Price change

A.I.dvisor tells us that JAZZ and RPRX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAZZ and RPRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.42%
RPRX - JAZZ
33%
Poorly correlated
-0.08%
BEAM - JAZZ
32%
Poorly correlated
+0.38%
DNA - JAZZ
32%
Poorly correlated
-0.95%
NTLA - JAZZ
32%
Poorly correlated
-0.41%
REGN - JAZZ
31%
Poorly correlated
-0.09%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with IDYA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.09%
IDYA - REGN
40%
Loosely correlated
-0.32%
MTNB - REGN
37%
Loosely correlated
+1.90%
INVA - REGN
36%
Loosely correlated
-0.06%
VRTX - REGN
35%
Loosely correlated
+0.72%
CRSP - REGN
34%
Loosely correlated
+1.14%
More